The Use of Low Molecular Weight Heparin Among COVID-19 Patients in Udayana University Hospital, Bali
DOI:
https://doi.org/10.33448/rsd-v11i10.31821Keywords:
COVID-19; Low Molecular Weight Heparin; Prophylaxis; Treatment.Abstract
Experts have speculated the potential of heparin administration as COVID-19 treatment modality, although scientific research regarding its effectivity, recommended dosage, and period are still minimal. This study aims to explore the capacity of LMWH as a medicament for COVID-19, in effort to provide scientific reference for further development of COVID-19 possible choice of treatment or medicament. A retrospective study was conducted in Udayana University Hospital, Bali, Indonesia. Data were sourced from laboratory-confirmed COVID-19 patients medical records during March 25 to July 31, 2020. Clinical, laboratory, treatment and use of LMWH data were reviewed and statistically processed. 42 patients we found Use of LMWH. The patient categorizes from moderate to severe COVID-19. 31 patients use of LMWH for prophylaxis and 11 patients use of LMWH for treatment. 7 patients were death in the hospital, and the other was survived. LMWH elevates coagulation dysfunction in COVID-19 patients. We believe that beneficial effects of LMWH as prophylaxis or treatment in COVID-19 patients.
References
Ayerbe, L., Risco, C., & Ayis, S. (2020). The association between treatment with heparin and survival in patients with Covid-19. Journal of Thrombosis and Thrombolysis, 50(2), 298–301. https://doi.org/10.1007/s11239-020-02162-z
Dahlan, S. (2013). Statistik Untuk Kedokteran dan Kesehatan. Penerbit Salemba. https://books.google.co.id/books?hl=id&lr=&id=Abh5OaO3qlMC&oi=fnd&pg=PA1&ots=SWVDMa00xU&sig=yEOdMqA_b5Jo3ZKRAGoYNY8s5Ww&redir_esc=y#v=onepage&q&f=false
Hendriks, S. A. (2017). Understanding The Clinical Course of Dementia. https://research.vu.nl/ws/portalfiles/portal/42577616/complete+dissertation.pdf
Hosseini, A., & Bahramnezhad, F. (2020). Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin. Sao Paulo Medical Journal, 138(4), 349–351. https://doi.org/10.1590/1516-3180.2020.0221.r2.22072020
Liu, Y., Lee, J. M., & Lee, C. (2020). The challenges and opportunities of a global health crisis: the management and business implications of COVID-19 from an Asian perspective. Asian Business and Management, 19(3), 277–297. https://doi.org/10.1057/s41291-020-00119-x
Paolisso, P., Bergamaschi, L., D’Angelo, E. C., Donati, F., Giannella, M., Tedeschi, S., Pascale, R., Bartoletti, M., Tesini, G., Biffi, M., Cosmi, B., Pizzi, C., Viale, P., & Galié, N. (2020). Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.01124
Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 18(4), 844–847. https://doi.org/10.1111/jth.14768
Zhang, J., Meng, G., Li, W., Shi, B., Dong, H., Su, Z., Huang, Q., & Gao, P. (2020). Relationship of chest CT score with clinical characteristics of 108 patients hospitalized with COVID-19 in Wuhan, China. Respiratory Research, 21(1). https://doi.org/10.1186/s12931-020-01440-x
Zhang, L., Dong, L., Ming, L., Wei, M., Li, J., Hu, R., & Yang, J. (2020). Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection during late pregnancy: a report of 18 patients from Wuhan, China. BMC Pregnancy and Childbirth, 20(1). https://doi.org/10.1186/s12884-020-03026-3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Saktivi Harkitasari; Cokorda Agung Wahyu Purnamasidhi; Ni Made Renny Anggreni Rena; Ni Made Dewi Dian Sukmawati; I Ketut Agus Somia
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
